Sarmad Said, Chad J. Cooper, S. Claudia Didia
Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, USA
Med Sci Rev 2014; 1:1-6
Over the last 2 decades several pharmacological approaches in the management of hypercholesterolemia were introduced. Some of these agents were labeled as a breakthrough therapy. Statins have proven to significantly, decrease levels of low-density lipoprotein and subsequently reduce the associated cardiovascular risk profile. However, their beneficial impact cannot be provided to all the patients without exceptions. Patients with certain genetic disorders and environmental influences cannot substantially benefit from statins. Therefore the search for a novel approach in the management of hypercholersterolemia and hyperlipidemia is essential. Phase-I and II clinical trials have demonstrated a significant clinical impact and favorable reduction of low-density lipoprotein levels. This comprehensive review focuses on the potential benefits of reported inhibitors on the proprotein convertase subtilisin/kexin type 9, currently undergoing further investigations.
Keywords: Hypercholesterolemia, Hyperlipidemias, Proprotein Convertases